GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) will report its 2022 financial results on March 23, 2023, after market close. The announcement will be followed by a live conference call at 4:30 PM ET, providing a general business update and financial discussion. Investors and analysts can join the call via domestic and international numbers or through a provided webcast link. GeoVax is developing innovative vaccines and immunotherapies for cancer and infectious diseases, including a next-generation COVID-19 vaccine, GEO-CM04S1, currently in two Phase 2 trials targeting high-risk populations.

Positive

• Upcoming financial results announcement may provide clarity on company performance.
• Ongoing clinical trials for innovative COVID-19 vaccine and cancer therapies indicate potential for future growth.

Negative

• None.

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time

ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes.

Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Thursday, March 23, 2023, 4:30 PM ET
Domestic:                   877-269-7756
International:              201-689-7817
Conference ID:           13736454
Webcast:                    GeoVax 2022 Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through June 23, 2023.

About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Investor Relations Contact:
Rich Cockrell
CG Capital
404-736-3838
govx@cg.capital

FAQ

When will GeoVax Labs report its 2022 financial results?

GeoVax Labs will report its 2022 financial results on March 23, 2023, after market close.

What time is the GeoVax conference call?

The GeoVax conference call is scheduled for 4:30 PM ET on March 23, 2023.

How can I participate in the GeoVax earnings call?

Participants can join the GeoVax earnings call via domestic number 877-269-7756 or international number 201-689-7817, and it will also be available via webcast.

What is GEO-CM04S1?

GEO-CM04S1 is GeoVax's next-generation COVID-19 vaccine, currently in Phase 2 clinical trials for high-risk patient populations.

What cancer therapy is GeoVax developing?

GeoVax is developing Gedeptin®, an oncolytic solid tumor gene-directed therapy currently in a Phase 1/2 clinical trial for advanced head and neck cancers.